Shots: Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole discretion in either cash or […]readmore
Tags : Hematological
Shots: Roche to receive upfront, development and commercial milestone payments plus royalties and retains option to license for each ex-China development and commercialization. Innovent to get non-exclusive access to certain […]readmore
Shots: Lupin to receive $30M upfront, up to $947M milestones and royalties on sales. AbbVie to get exclusive worldwide (Ex. India) rights to develop and commercialize Lupin’s MALT1 inhibitors The focus of the agreement […]readmore